Goodwin’s Technology M&A team advised Pathology Watch in its entry into a definitive agreement to be acquired by Sonic Healthcare Limited (ASX: SHL). The transaction, with the purchase price of $130 million, is subject to customary conditions and is expected to close in December 2023.
Pathology Watch is a medical technology business that has developed and commercialized an integrated, end-to-end digital pathology platform for skin pathology (dermatopathology). It was recently named as part of the Inc. 500 fastest growing private companies in America.
Sonic Healthcare is one of the world's largest anatomical pathology providers.
The Goodwin team was led by Pete Fusco and Kirkie Maswoswe and included Jesse Kalashyan, Ryan Johnson, Youngjin Jang (Technology M&A), William Wilson, David Scott (Intellectual Property), Roger Cohen, Rebecca Kennedy (Healthcare), George Davis, Chris Zhao (Tax), Alexandra Denniston, Adrean Williams, Benjamin Kurrass, Rahat Tariq (Executive Compensation), Timothy Holahan, Alastair Papworth (Labor & Employment), Paul Jin, Michael Casaburi, Nicholas Pellow (Antitrust), Steven Tjoe (FDA), Cecelia Lockner (Insurance), Federica De Santis (Data Privacy), Amy Josselyn, Ce Li (Global Trade), with invaluable assistance from Matthew Mancini, Hannah Waldman, Michael Fahner and Keith Janowitz.
For more details, read the press release.